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In a population-based case-control study of community-
acquired Clostridium difﬁ  cile–associated disease (CDAD), 
we matched 1,233 cases to 12,330 controls. CDAD risk 
increased 3-fold with use of any antimicrobial agent and 6-
fold with use of ﬂ  uoroquinolones. Prior use of antimicrobial 
agents did not affect risk for CDAD after 6 months.
R
ecent reports suggest that Clostridium difﬁ  cile–as-
sociated disease (CDAD), including community-ac-
quired CDAD, is increasing in occurrence and severity 
(1–4). Antimicrobial drug use is widely believed to be a 
key driver of CDAD infections, with differences in risk 
depending on class of antimicrobial agent (2). Differ-
ences in risk are postulated to be caused by differences 
in properties of the microbial agents, such as the magni-
tude and the duration of their effects on the fecal ﬂ  ora (5), 
their activity against C. difﬁ  cile, and possibly their drug 
or metabolite levels in the intestinal lumen (6). However, 
most studies of CDAD and antimicrobial drugs have been 
hospital based. Because inpatients are often exposed to 
multiple antimicrobial drugs, these studies may have lim-
ited ability to evaluate agents rarely prescribed or rarely 
prescribed alone (e.g., macrolides).
We expand on previous work by assessing whether 
and to what extent the risk for community-acquired CDAD 
varies with the type of antimicrobial drug prescribed. We 
also evaluate whether and how long this effect takes to dis-
sipate after drug discontinuation, beyond the 90-day period 
previously explored with this population (3,4).
The Study
We further analyzed data from a population-based 
case-control study that was constructed using the United 
Kingdom’s General Practice Research Database (GPRD). 
GPRD is a well-validated (7) clinical database that records 
information taken from general practice records. The co-
hort used in this study has been extensively described (3).
Brieﬂ  y, we identiﬁ  ed all patients who had had CDAD 
(based on either clinical diagnosis or a positive toxin test 
result) from 1993 through 2004 and who were registered 
for >2 years in a general practice anywhere in the United 
Kingdom. Approximately 90% of tests for C. difﬁ  cile toxin 
had neither a positive nor negative result in the GPRD (the 
result was not recorded as a variable but may be included as 
case notes that we were unable to review), and so a clinical 
diagnosis often indicates a test result that was not available 
to the investigators. Case-patients were deﬁ  ned as patients 
with community-acquired CDAD, that is, patients who had 
not been not hospitalized during the year before their CDAD 
diagnosis. Each case-patient was matched by practice and 
age (±2 years) to 10 control-patients who also had not been 
hospitalized during the prior year.  Control-patients were 
also registered in the GPRD for at least 2 years. By match-
ing these control-patients to speciﬁ  c case-patients, we could 
assess the antimicrobial use in the source population from 
which the case-patients arose. Control-patients had the same 
index date as the case-patient to which they were individu-
ally matched, which enabled us to account for changing drug 
patterns and disease rates over time in this database. We used 
the British National Formulary to deﬁ  ne the following anti-
microbial drug classes: penicillins, cephalosporins and other 
β-lactams, tetracyclines, macrolides, sulfonamides and trim-
ethoprim, ﬂ  uoroquinolones, and all others.
A total of 1,233 case-patients were matched to 12,330 
control-patients. The results of antimicrobial exposure, by 
drug class, are presented in Table 1. The adjusted odds ra-
tio (OR) for CDAD with use of any antimicrobial drug in 
the 90 days before the index date was 3.1 (95% conﬁ  dence 
interval [CI]: 2.7–3.6). Adjusted ORs for different class-
es of antimicrobial drugs were as follows: tetracyclines 
0.85, sulfonamides 1.88, penicillins 1.89, macrolides 2.15, 
cephalosporins 2.21, and ﬂ  uoroquinolones 6.20. The mean 
number of antimicrobial classes for those who received the 
drugs was 1.4 for case-patients and 1.2 for control-patients. 
With respect to patients who received at least 1 antimicro-
bial drug, 67% of case-patients and 82% of control-patients 
received only 1 class of antimicrobial drug (compared with 
50% of case-patients and 59% of control-patients among 
ﬂ  uoroquinolone users who received only a single class of 
antimicrobial drug).
Table 2 describes the residual effects after discontinu-
ation of antimicrobial agents, ﬂ  uoroquinolones in particu-
lar, as a function of the time since the last prescription. The 
risk (OR 3.1, CI 2.7–3.6) with current antimicrobial drug 
use diminished after 3 months, dropped to OR 1.8 (95% CI 
1.4–2.3), and essentially disappeared after 6 months (OR 
1.3, 95% CI 1.0–1.6). A similar pattern was observed after 
discontinuation of ﬂ  uoroquinolone use. This is much lower 
than the effect in the 90-day window before diagnosis with 
CDAD.
To reduce the risk for protopathic bias (8), we did a 
sensitivity analysis in which we considered any patient  *McGill University Health Center, Montreal, Quebec, CanadaDISPATCHES
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who had a recent (90-day) diagnosis of infectious diarrhea 
to be unexposed to ﬂ  uoroquinolones. This analysis reduced 
the size of the adjusted OR for ﬂ  uoroquinolone use from 
6.2 (95% CI 4.4–8.8) to 5.0 (95% CI 4.4–7.2).
We also conducted sensitivity analyses based on the 
source of the CDAD diagnosis (test-based or clinical only). 
These analyses showed a similar effect for exposure to any 
antimicrobial agents for clinical and test-based diagnoses. 
Among antimicrobial classes, although ﬂ  uoroquinolones 
appear to have higher ORs in the test-based group (OR 6.7; 
95% CI 4.5–10.0) than in the group with clinically based 
diagnoses (OR 5.2; 95% CI 2.6–10.6), this difference is not 
statistically different. All other antimicrobial agents were 
stronger risk factors for development of CDAD when the 
deﬁ  nition of CDAD was determined by clinical diagnosis 
alone, without a toxin-positive test result.
Conclusions 
Almost all antimicrobial drugs were associated with 
increased risk for community-acquired CDAD. The risk as-
sociated with ﬂ  uoroquinolones was particularly elevated, 
as has been found in other recent studies on CDAD in hos-
pital settings (2,9–11).
Because broad-spectrum antimicrobial drugs are 
more commonly prescribed for patients with more severe 
infections, the underlying indications for ﬂ  uoroquinolone 
prescription could also be contributing to the increased 
risk for CDAD. That is, channeling of antimicrobial drugs 
toward such patients may result in confounding by indi-
cation (12). The sharp reduction in residual risk among 
ﬂ  uoroquinolone users suggests that chronic health status 
confounding is likely to be minor. Although the residual 
effects of antimicrobial prescriptions never drop to zero 
(which may indicate a minor effect of confounding), they 
drop signiﬁ  cantly and quickly. This does not exclude the 
possibility of confounding by indication due to the infec-
tion for which the ﬂ  uoroquinolone was prescribed. 
In addition, our sensitivity analysis suggested some 
degree of robustness of this result because of misclassiﬁ  -
cation, from either misdiagnosis of CDAD as another form 
of diarrhea or from the source of the diagnosis. However, 
despite the high sensitivity and speciﬁ  city seen in stud-
ies that use database codes to identify CDAD cases (13) 
and the successful use of this approach in other studies 
(14,15), more validation work on this endpoint remains to 
be done to completely describe the process of recording 
Table 1. Antimicrobial drug exposure of patients with and without Clostridium difficile–associated disease, UK, 1993–2004* 
Antimicrobial drug received, past 90 d 
Case-patients,
n = 1,233 (%) 
Control-patients,  
n = 12,330 (%)  Crude OR† 
Adjusted OR‡
(95% CI) 
Any   456 (37)  1649 (13)  5.0 3.7 (3.1–4.4) 
Tetracyclines  17 (1.4)  106 (0.9)  1.0 0.9 (0.5–1.5) 
Penicillins 202 (16.4)  790 (6.4)  2.4 1.9 (1.6– 2.4) 
Sulfonamides and trimethoprim  71 (5.7)  236 (1.9)  2.3 1.9 (1.5–2.7) 
Macrolides 80 (6.5)  219 (1.7)  2.7 2.2 (1.7–3.1) 
Cephalosporins and other β-lactams  76 (6.2)  207 (1.7)  2.9 2.2 (1.7–3.2) 
Fluoroquinolones  70 (5.7)  84 (0.7)  10.9 6.2 (4.4– 8.8) 
*OR, odds ratio; CI, confidence interval. 
†Adjusted for other antimicrobial drugs and prior antimicrobial drug use to ensure that all comparisons used the same reference group. 
‡Adjusted for inflammatory bowel disease, diverticular disease, peptic ulcer disease and gastroesophageal reflux disease, Helicobacter pylori–associated 
disease, pernicious anemia, cancer including solid tumor and hematologic malignancies, diabetes mellitus, chronic obstructive pulmonary disease, 
cirrhosis, nonsteroidal anti-inflammatory agents, aspirin, H2 blockers, proton pump inhibitors, and antimicrobial drug use in the past 2 years. 
Table 2. Most recent prescription for any antimicrobial drug and effect of proximity on risk of acquiring Clostridium difficile–associated
disease, UK, 1993–2004* 
Exposure to antimicrobial drug 
Case-patients,
n = 1,233 (%) 
Control-patients, 
n = 12,330  Crude OR  Adjusted OR (95% CI)† 
None (reference)  379 (30)  6,449 (52)  1.0 1.0 (reference) 
Most recent prescription‡ 
1–90 d (current)  456 (37)  1,649 (13)  5.0 3.7 (3.1–4.4) 
91–180 d 128 (10)  1067 (9)  2.2 1.8 (1.4–2.3) 
181–365 d  131 (11)  1,498 (12)  1.6 1.3 (1.0–1.6) 
1–2 y  139 (11)  1,674 (13)  1.5 1.3 (1.0–1.6) 
Most recent fluoroquinolone prescription†  
1 – 90 d (current)  70 (5.7)  84 (0.7)  10.9 6.2 (4.4–8.8) 
91–180 d 12 (1.0)  70 (0.6)  1.7 1.2 (0.6–2.3) 
181–365 d  27 (2.2)  114 (0.9)  2.4 1.7 (1.1–2.7) 
1–2 y  36 (2.9)  198 (1.6)  1.9 1.3 (0.9– 2.0) 
*OR, odds ratio; CI, confidence interval. 
†Adjusted for inflammatory bowel disease, diverticular disease, peptic ulcer disease and gastroesophageal reflux disease, Helicobacter pylori–associated 
disease, pernicious anemia, cancer including solid tumor and hematologic malignancies, diabetes mellitus, chronic obstructive pulmonary disease, 
cirrhosis, nonsteroidal anti-inflammatory agents, aspirin, H2 blockers, proton pump inhibitors, and antimicrobial use in the past 2 years. 
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community-based CDAD diagnoses.
Our results suggest that antimicrobial drugs are a risk 
factor for CDAD, including community-acquired CDAD. 
Despite the high risk that appears to be associated with 
ﬂ  uoroquinolone use, only 7% of the case-patients in this 
sample were exposed to a ﬂ  uoroquinolone, and only 37% 
were exposed to any class of antimicrobial drug. Therefore, 
while good prescribing practices for antimicrobial drugs 
should continue to be encouraged, these drugs are unlikely 
to be the primary driver of community-acquired CDAD in-
fections in this population. 
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